Gene · 1294
Papers2,575
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
141 to 160 of 2,575
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Functional genotype classification groups distinguish disease severity in recessive dystrophic epidermolysis bullosa. | Br J Dermatol | 2025 | 39790012 | PubTator, text mining | PubMed |
| The power of next-generation-sequencing: A game-changer with limitations. | J Eur Acad Dermatol Venereol | 2025 | 39711441 | PubTator, text mining | PubMed |
| Genetic Insights Into Epidermolysis Bullosa: Identification of Novel Variants in Tunisian Patients. | Am J Med Genet A | 2025 | 39688128 | PubTator, text mining | PubMed |
| Novel variants impairing Sp1 transcription factor binding in the COL7A1 promoter cause mild cases of recessive dystrophic epidermolysis bullosa. | Eur J Hum Genet | 2025 | 39639148 | PubTator, text mining | PubMed |
| Use of multivariant enzyme-linked immunosorbent assay (ELISA) in the diagnosis of autoimmune bullous disorders in a resource-limited setting: A single-center experience. | Indian J Dermatol Venereol Leprol | 2025 | 39635793 | PubTator, text mining | PubMed |
| Clinical and Genetic Findings in Patients With Palmoplantar Keratoderma. | JAMA Dermatol | 2025 | 39630431 | PubTator, text mining | PubMed |
| New recessive dystrophic epidermolysis bullosa intermediate variant resulting from alternative splicing of exon 19 and truncation in the fibronectin III-like domain of type VII collagen. | Br J Dermatol | 2025 | 39391914 | PubTator, text mining | PubMed |
| Collagen VII's Dual Mesenchymal and Epithelial Origins: Implications for Molecular Corrective Therapies. | J Invest Dermatol | 2025 | 38980231 | PubTator, text mining | PubMed |
| A case of epidermolysis bullosa pruriginosa with a COL7A1 gene mutation successfully treated with upadacitinib. | J Dermatol | 2025 | 38660959 | PubTator, text mining | PubMed |
| RETRACTED: Exploring the tumor microenvironment: Chemokine-related genes and immunotherapy/chemotherapy response in clear-cell renal cell carcinoma. | Environ Toxicol | 2025 | 38488671 | PubTator, text mining | PubMed |
| Summary report of the 1st MOVE symposium in Málaga from 24-27th October 2023 - Foster the European mobility for young scientists in extracellular vesicles research. | Extracell Vesicles Circ Nucl Acids | 2024 | 39698417 | PubTator, text mining | PubMed |
| Increased frequency of CHEK2 germline pathogenic variants among individuals with dermatofibrosarcoma protuberans. | Genet Med Open | 2024 | 39669616 | PubTator, text mining | PubMed |
| A homozygous nonsense mutation identified in COL7A1 in a family with autosomal recessive dystrophic epidermolysis bullosa. | J Med Life | 2024 | 39628969 | PubTator, text mining | PubMed |
| Systemic treatment of recessive dystrophic epidermolysis bullosa with mesenchymal stromal cells: a scoping review of the literature and conclusions for future clinical research. | J Dermatolog Treat | 2024 | 39551482 | PubTator, text mining | PubMed |
| Current Status of Biomedical Products for Gene and Cell Therapy of Recessive Dystrophic Epidermolysis Bullosa. | Int J Mol Sci | 2024 | 39408598 | PubTator, text mining | PubMed |
| Novel readthrough agent suppresses nonsense mutations and restores functional type VII collagen and laminin 332 in epidermolysis bullosa. | Mol Ther Nucleic Acids | 2024 | 39391765 | PubTator, text mining | PubMed |
| Efficacy of rituximab in the treatment of epidermolysis bullosa acquisita. | Clin Exp Dermatol | 2024 | 39387486 | PubTator, text mining | PubMed |
| Regionally enriched rare deleterious exonic variants in the UK and Ireland. | Nat Commun | 2024 | 39358353 | PubTator, text mining | PubMed |
| The COL7A1/PI3K/AKT axis regulates the progression of cholangiocarcinoma. | Heliyon | 2024 | 39309925 | PubTator, text mining | PubMed |
| Autosomal recessive type of dystrophic epidermolysis bullosa with a novel variant in the COL7A1 gene. | Biomed Rep | 2024 | 39301563 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/1294/papers?page=8